PRODUCT BULLETIN

nCounter® Tumor Signaling 360 Panel
Gene Expression Panel
Targeted Therapeutics • Tumor Signaling • Immune Response

Covering hundreds of genes involved in tumorigenesis, metastasis, and inflammation, the nCounter Tumor Signaling 360 Panel offers a holistic
view of the biology of the tumor, microenvironment, and immune response with an emphasis on dysfunctional cell signaling in cancer. Identify
targets for novel therapies and understand the mechanism of action for current ones with a comprehensive look at 40+ pathways involved intumor biology, immune evasion, and remodeling of the microenvironment.

GANG
GEN

IO G E N E SISRSEVADSU IN GPPRESSOGINI S T THR E S DE A
LCE L

INO
IN R - P R O M OTN
FL A
M M ATI O

TH

TUMM

Product Highlights•

Profile 780 human and mouse across 40+ annotatedpathways involved in tumor signaling•

Assess altered signaling pathways•

Identify targets for novel therapeutics•Understand the mechanism of action of targetedtherapies•

Measure the anti-tumor immune response•

Quantify the relative abundance of immune cell types

OW

INVASIOE EVASMUNIONIMED
AIN TIONSTASU IFEROL
PRNISTAS
ASET

REP
L
IMM ICATORTA IVELITY

CELLULAR
ENERGETICSGROMIC INSTABILIT Y& MUTATIONFeatureSpecifications

Number of Targets

780 (Human), 780 (Mouse), including internal reference genes

Sample Input - Standard (No amplification required)25-300 ng

Sample Input - Low Input

As little as 1 ng with nCounter Low Input Kit (sold separately)Sample Type(s)Cultured cells/cell lysates, sorted cells, FFPE-derived RNA, total RNA, fragmented RNA,PBMCs, and whole blood/plasma

Customizable

Add up to 55 unique genes with Panel Plus

Time to Results

Approximately 24 hours

Data Analysis

nSolver™ Analysis Software (RUO) and the ROSALIND® Platform

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

1nCounter® Tumor Signaling 360 Panel

PRODUCT BULLETIN

Core Themes and Annotations
The nCounter 360 series of cancer gene expression panels have been developed to comprehensively profile the tumor, immune response,and microenvironment. As therapeutics that target tumor signaling evolve, a greater understanding of tumor signaling is required as well as abetter understanding of the interactions of tumor cells with the tissue milieu. The Tumor Signaling 360 Panel is intended to play this exact role,enabling deeper profiling of the tumor that is complete, yet focused on signaling pathways of interest for targeted therapeutic development.
Tumor Signaling
Cellular Energetics(Hs/Mm)Sustained Proliferation(Hs/Mm)Evading GrowthSuppressors(Hs/Mm)Enabling ReplicativeImmortality(Hs/Mm)Genomic Instability &Mutation(Hs/Mm)Resisting Cell Death(Hs/Mm)

105/104 Genes

223/221 Genes

79/79 Genes

48/48 Genes

111/111 Genes

23/23 Genes

Autophagy

Androgen Signaling

Cell Cycle

Immortality & Stemness

DNA Damage & Repair

Apoptosis

GlucoseMetabolism

EGFR Signaling

Senescence

Epigenetic &TranscriptionalRegulation

TNF Superfamily

Glutamine Metabolism

ERBB2 Signaling

Lipid Metabolism

Estrogen SignalingmTOR Signaling

FGFR Signaling

Nrf2 & Oxidative StressHedgehog

p53 Signaling

MAPK Signaling
MET Signaling
MycNotch Signaling
PI3K-Akt Signaling
TGF-beta Signaling
Wnt Signaling

Immune Response
Immune Evasion(Hs/Mm)122/124 Genes

Tumor-Promoting Inflammation(Hs/Mm)178/171 Genes

Tumor Microenvironment
Activating Invasion and Metastasis(Hs/Mm)146/146 Genes

Angiogenesis(Hs/Mm)67/67 Genes

Antigen Presentation

Chemokine Signaling

Cell Adhesion & Motility

HIF1 Signaling

B cell Function

Inflammation

ECM Remodeling & Metastasis

PDGF Signaling

Cytotoxicity

Interferon Response

EMT

VEGF Signaling

Myeloid Immune Evasion

JAK-STAT Signaling

Hippo Signaling

T cell Co-stimulation

NF-kB Signaling

T cell Exhaustion
TCR Signaling
Tumor Antigen

To view the annotated gene lists for the Tumor Signaling 360 Panel, visit nanostring.com/TS360nSolver™ Analysis Software

ROSALIND® Platform

NanoString offers advanced software tools that address thecontinuous demands of data analysis and the need to get
simple answers to specific biological questions easily. Genes
included in the Tumor Signaling 360 Panel are organized andlinked to various advanced analysis modules.

ROSALIND is a cloud-based platform for life science research that enables scientists
to analyze and interpret differential gene expression data without need forbioinformatics or programming skills. ROSELIND makes analysis for nCounter dataeasy, with guded modules for:Normalization / Quality Control / Individual Pathway Analysis
Differential Expression / Gene Set Analysis
nCounter customers can access ROSALIND free of charge at rosalind.bio/nanostring.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

2NanoString Technologies, Inc.

nCounter® Tumor Signaling 360 Panel

Immune Cell Profiling Feature
Genes included in the Tumor Signaling 360 Panel provide unique cell profiling data to measure the relative abundance of 14 different humanimmune cell types. The table below summarizes each cell type represented by gene content in the panel, as qualified through biostatistical
approaches and selected literature in the field of immunology.
Cell Type

Associated Human Genes

B Cells

BLK, CD19, FAM30A, FCRL2, MS4A1, PNOC, SPIB, TCL1A, TNFRSF17

CD45

PTPRC

CD8

CD8A, CD8B

Cytotoxic Cells

CTSW, GNLY, GZMA, GZMB, GZMH, KLRB1, KLRD1, KLRK1, NKG7, PRF1

Dendritic Cells

CCL13, CD209, HSD11B1

Exhausted CD8CD244, EOMES, LAG3, PTGER4Macrophages

CD163, CD68, CD84, MS4A4A

Mast Cells

CPA3, HDC, MS4A2, TPSAB1/B2

Neutrophils

CEACAM3, CSF3R, FCAR, FCGR3A/B, FPR1, S100A12, SIGLEC5

NK Cells

NCR1, XCL1/2

NK CD56dim Cells

IL21R, KIR2DL3, KIR3DL1, KIR3DL2

T Cells

CD3D, CD3E, CD3G, CD6, SH2D1A, TRAT1

Th1 Cells

TBX21

Treg

FOXP3

Tumor Inflammation Signature
Included within the Tumor Signaling 360 panel is the Tumor Inflammation Signature (TIS). This 18-gene signature measures activity known to be
associated with response to PD-1/PD-L1 inhibitors.

•Measures 4 axes of biology to characterize a peripherally
suppressed immune response-Antigen Presenting Cells-T Cell/NK Presence-IFNγ Biology-T Cell Exhaustion

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

•Tissue-of-origin agnostic (Pan-cancer)•

Potential surrogate for PD-L1 and mutational load in aresearch setting

3

nCounter® Tumor Signaling 360 Panel

PRODUCT BULLETIN

Ordering Information
Gene Expression Panels arrive ready-to-use and generally ship within 24 hours following purchase.
ProductProduct Description

Quantity

Catalog NumbernCounter Human Tumor Signaling 360
Panel

Gene Expression CodeSet profiling (780 genes) 760 tumor signaling
related genes + 20 internal reference controls. No Master Kit

12Reactions

XT-CSO-H-TS360-12

nCounter Human Tumor Signaling 360
Panel Standard

Standard containing a pool of synthetic DNA oligonucleotides
that correspond to the target sequence of each of the 780 uniqueprobe targets in the panel.

12
Reactions

PSTD-H-T360-12

nCounter Mouse Tumor Signaling 360
Panel

Gene Expression CodeSet profiling (780 genes) 760 tumor signaling
related genes + 20 internal reference controls. No Master Kit

12Reactions

XT-CSO-M-TS360-12

nCounter Mouse Tumor Signaling 360
Panel Standard

Standard containing a pool of synthetic DNA oligonucleotides
that correspond to the target sequence of each of the 780 uniqueprobe targets in the panel.

12Reactions

PSTD-M-T360-12

nCounter Analysis System
Master Kit Reagents and Cartridges

Reagents, cartridges, and consumables necessary for sample
processing on the nCounter Analysis System

12Reactions

NAA-AKIT-012

nCounter SPRINT Cartridge(1 Cartridge, 12 lanes)

Sample Cartridge for nCounter SPRINT System

12Reactions

SPRINT-CAR-1.0

nCounter SPRINT Reagent PacknCounter SPRINT Reagent Pack containing Reagents A, B, C, andHybridization Buffer

192
Reactions

SPRINT-REAG-KITLow Input RNA Reagent Kit

48 rxn kit for profiling from low sample input amounts

48
Reactions

LOW-RNA-48

Selected Publications
1.

Bieging KT and Attardi LD. Deconstructing p53 Transcriptional Networks in Tumor Suppression. Trends Cell Biol. 2012; 22 (2), 97-106.

2.

Bild, AH et al. Oncogenic Pathway Signatures in Human Cancers as a Guide to Targeted Therapies. Nature. 2006;439 (7074), 353-7.

3.

Chiaradonna, F. Ras-dependent Carbon Metabolism and Transformation in Mouse Fibroblasts. Oncogene. 2006;25 (39), 5391-404.

4.

Cordenonsi, M et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell. 2011;147(4):759-72.

5.

Hanahan D and Weinberg, RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.

6.

Danaher, P et al. Gene Expression Markers of Tumor Infiltrating Leukocytes. J Immunother Cancer. 2017;21(5):18.

7.

Jia, P and Zhao Z. Characterization of Tumor-Suppressor Gene Inactivation Events in 33 Cancer Types. Cell Reports. 2019;26, 496–506.

8.

Malta, TM et al. Machine Learning Identifies Stemness Features Associated With Oncogenic Dedifferentiation. Cell. 2018;173(2): 338-354.e15.

9.

Sanchez-Vega F et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018; 173 (2), 321-337.e10.

10.

Semenza, GL Hypoxia-inducible Factor 1: Oxygen Homeostasis and Disease Pathophysiology. Trends Mol Med. 2001;7(8):345-50.

11.

Singh, A et al. RNAi-mediated Silencing of Nuclear Factor erythroid-2-related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor
Growth and Increases Efficacy of Chemotherapy. Cancer Res. 2008; 68 (19), 7975-84.

12.

Sun, J et al. A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology. 2017, 11(Suppl 5):87.

13.

Sweet-Cordero A et al. An Oncogenic KRAS2 Expression Signature Identified by Cross-Species Gene-Expression Analysis. Nat Genet. 2005; 37 (1), 48-55.

14.

Way, GP et al. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep. 2018;23(1): 172-180.e3.

For more information, please visit nanostring.com
NanoString Technologies, Inc.
T (888) 358-6266
530 Fairview Avenue NorthF (206) 378-6288
Seattle, Washington 98109

nanostring.com
info@nanostring.com

Sales Contacts
United States us.sales@nanostring.com
EMEA: europe.sales@nanostring.com

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
© 2017-2022 NanoString Technologies, Inc. All rights reserved. NanoString, NanoString Technologies, nCounter, nSolver, and the NanoSTring logo areregistered trademarks of NanoString Technologies, Inc., in the United States and/or other countries.
APR 2022 MK2217

Asia Pacific & Japan apac.sales@nanostring.com
Other Regions info@nanostring.com